zoledronic acid has been researched along with Experimental Mammary Neoplasms in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 14 (73.68) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Du, Y; Jin, Z; Li, Y; Sun, T; Tian, J; Xue, H | 1 |
| Battistelli, S; Magnani, M; Rossi, L; Sabatino, R | 1 |
| Alzhrani, RF; Cui, Z; Hufnagel, S; Hursting, SD; Li, X; Valdes, SA | 1 |
| Evdokiou, A; Fung, KP; Ko, CH; Lau, CB; Lee, JK; Lee, MY; Leung, PC; Li, G; Luo, KW; Shum, WT; Siu, WS; Yue, GG | 1 |
| Abbadessa, G; Broggini, M; Chilà, R; Previdi, S; Ricci, F; Scolari, F | 1 |
| Evdokiou, A; Fung, KP; Gao, S; Ko, CH; Lau, CB; Lee, JK; Leung, PC; Li, G; Luo, KW; Yue, GG | 1 |
| Gao, D; Gao, L; Jia, B; Liu, Z; Sun, X; Wang, F; Yu, X; Zhang, C | 1 |
| Fung, KP; Gao, S; Ko, CH; Lau, CB; Lee, JK; Leung, PC; Li, G; Luo, KW; Yue, GG | 1 |
| Ding, D; Du, Y; He, ZQ; Jia, XH; Ma, XB; Mao, D; Qiu, JD; Shang, WT; Tian, J; Wang, ZL | 1 |
| Baklaushev, VP; Burenkov, MS; Chekhonin, VP; Grinenko, NF; Gubskii, IL; Ivanova, NV; Rabinovich, EZ; Yusubalieva, GM | 1 |
| Coleman, RE; Holen, I; Jones, M; Lefley, DV; Mönkkönen, H; Ottewell, PD | 1 |
| Coleman, RE; Cross, SS; Evans, CA; Holen, I; Lefley, DV; Ottewell, PD | 1 |
| Brown, HK; Brown, NJ; Coleman, RE; Cross, SS; Holen, I; Jones, M; Ottewell, PD; Rogers, TL | 1 |
| Blumer, KJ; Chinault, SL; Kaltenbronn, KM; Penly, A; Piwnica-Worms, D; Prior, JL; Weilbaecher, KN | 1 |
| Abdelkarim, M; Crepin, M; Di Benedetto, M; Jais, JP; Kassis, N; Lecouvey, M; Perret, GY; Vintonenko, N | 1 |
| Hata, K; Hiraga, T; Ikeda, F; Tamura, D; Ueda, A; Williams, PJ; Yoneda, T | 1 |
| Clézardin, P; Daubiné, F; Gasser, J; Green, J; Le Gall, C | 1 |
| Barazzetta, FM; Colombo, MP; Melani, C; Sangaletti, S; Werb, Z | 1 |
| Hiraga, T; Mundy, GR; Yoneda, T | 1 |
1 review(s) available for zoledronic acid and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
Topics: Animals; Bone and Bones; Bone Neoplasms; Diphosphonates; Drug Evaluation, Preclinical; Imidazoles; Mammary Neoplasms, Experimental; Mice; Models, Animal; Neoplasm Metastasis; Rats; Zoledronic Acid | 2001 |
18 other study(ies) available for zoledronic acid and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Animal; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Programmed Cell Death 1 Receptor; Zoledronic Acid | 2018 |
Preclinical evaluation of an innovative anti-TAM approach based on zoledronate-loaded erythrocytes.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Erythrocyte Transfusion; Erythrocytes; Female; Immunoglobulin G; Macrophages; Mammary Neoplasms, Experimental; Mice; Tumor Microenvironment; Xenograft Model Antitumor Assays; Zoledronic Acid | 2018 |
Zoledronic Acid-containing Nanoparticles With Minimum Premature Release Show Enhanced Activity Against Extraskeletal Tumor.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Delayed-Action Preparations; Female; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Nanoparticles; Tissue Distribution; Zoledronic Acid | 2019 |
Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models.
Topics: Administration, Metronomic; Animals; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Mammary Neoplasms, Experimental; Mice; Neoplasm Metastasis; Osteolysis; Radiography; Tumor Burden; Zoledronic Acid | 2013 |
Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Female; Heterografts; Humans; Imidazoles; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; X-Ray Microtomography; Zoledronic Acid | 2013 |
The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
Topics: Administration, Metronomic; Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Camellia sinensis; Cell Line, Tumor; Diphosphonates; Drug Therapy, Combination; Female; Imidazoles; Liver Neoplasms; Luminescent Measurements; Lung Neoplasms; Mammary Neoplasms, Experimental; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Osteolysis; Plant Extracts; Zoledronic Acid | 2015 |
Molecular imaging of tumor-infiltrating macrophages in a preclinical mouse model of breast cancer.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Diphosphonates; Docetaxel; Female; Imidazoles; Lectins, C-Type; Lung Neoplasms; Macrophages; Mammary Neoplasms, Experimental; Mannose Receptor; Mannose-Binding Lectins; Mice; Mice, Inbred BALB C; Receptors, Cell Surface; Sensitivity and Specificity; Spectroscopy, Near-Infrared; Taxoids; Zoledronic Acid | 2015 |
The combined use of Camellia sinensis and metronomic zoledronate in 4T1 mouse carcinoma against tumor growth and metastasis.
Topics: Administration, Metronomic; Animals; Camellia sinensis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphosphonates; Drug Therapy, Combination; Female; Gene Expression Regulation, Neoplastic; Imidazoles; Mammary Neoplasms, Experimental; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Neoplasm Metastasis; Osteolysis; Plant Extracts; Zoledronic Acid | 2015 |
Zoledronic acid prevents the tumor-promoting effects of mesenchymal stem cells via MCP-1 dependent recruitment of macrophages.
Topics: Animals; Bone Density Conservation Agents; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured; Chemokine CCL2; Cytokines; Diphosphonates; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Immunohistochemistry; Lectins, C-Type; Luciferases; Luminescent Measurements; Macrophages; Mammary Neoplasms, Experimental; Mannose Receptor; Mannose-Binding Lectins; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice, Inbred C57BL; Mice, Nude; Receptors, Cell Surface; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Mono- and Combined Therapy of Metastasizing Breast Carcinoma 4T1 with Zoledronic Acid and Doxorubicin.
Topics: Animals; Breast Neoplasms; Diphosphonates; Disease Models, Animal; Doxorubicin; Female; Imidazoles; Magnetic Resonance Imaging; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Zoledronic Acid | 2016 |
Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Caspase 3; Cell Proliferation; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Synergism; Female; Humans; Imidazoles; Immunohistochemistry; Ki-67 Antigen; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Research Design; Tomography, X-Ray Computed; Zoledronic Acid | 2008 |
Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Diphosphonates; Doxorubicin; Drug Administration Schedule; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Kaplan-Meier Estimate; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Reverse Transcriptase Polymerase Chain Reaction; Tumor Burden; Xenograft Model Antitumor Assays; Zoledronic Acid | 2010 |
Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Cell Proliferation; Diphosphonates; Disease Models, Animal; Disease Progression; Doxorubicin; Female; Imidazoles; Immunocompetence; Macrophages; Male; Mammary Neoplasms, Experimental; Mice; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Zoledronic Acid | 2012 |
Breast cancer cell targeting by prenylation inhibitors elucidated in living animals with a bioluminescence reporter.
Topics: Alkyl and Aryl Transferases; Animals; Benzamides; Blotting, Western; Bone Density Conservation Agents; Breast Neoplasms; Cell Line, Tumor; Clodronic Acid; Diphosphonates; Female; Genes, Reporter; Green Fluorescent Proteins; HEK293 Cells; Humans; Imidazoles; Luciferases; Luminescent Measurements; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Microscopy, Confocal; Mutation; Protein Prenylation; Recombinant Fusion Proteins; Transplantation, Heterologous; Zoledronic Acid | 2012 |
Transcriptome analysis and in vivo activity of fluvastatin versus zoledronic acid in a murine breast cancer metastasis model.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Disease Progression; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gene Expression; Gene Expression Profiling; Humans; Imidazoles; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Metastasis; Transcriptome; Zoledronic Acid | 2012 |
Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Diphosphonates; Disease Models, Animal; Drug Combinations; Female; Fluorouracil; Imidazoles; Luciferases; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Osteoclasts; Tegafur; Uracil; Zoledronic Acid | 2003 |
Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
Topics: Absorptiometry, Photon; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Drug Administration Schedule; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Imidazoles; Luciferases; Mammary Neoplasms, Experimental; Mice; Osteolysis; Research Design; Zoledronic Acid | 2007 |
Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Colony-Forming Units Assay; Diphosphonates; Female; Hematopoiesis; Imidazoles; Immune Tolerance; Immunotherapy; Macrophages; Male; Mammary Neoplasms, Experimental; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Myeloid Cells; Neovascularization, Pathologic; Receptor, ErbB-2; Stromal Cells; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2007 |